Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment DOI Creative Commons

Suming Wang,

Victor Zota,

Melanie Y. Vincent

et al.

npj Precision Oncology, Journal Year: 2024, Volume and Issue: 8(1)

Published: Dec. 3, 2024

Abstract Despite the development of cancer biomarkers and targeted therapies, most patients do not have a specific biomarker directly associated with effective treatment options. We developed VT1021 that induces expression thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to tumor microenvironment (TME). Our studies identified CD36 CD47 as dual can be used patient stratifying tools prognostic for treatment.

Language: Английский

Peptide‑based therapeutic strategies for glioma: current state and prospects DOI
Yajing Mi,

Pengtao Jiang,

Jing Luan

et al.

Peptides, Journal Year: 2025, Volume and Issue: 185, P. 171354 - 171354

Published: Feb. 6, 2025

Language: Английский

Citations

0
Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment DOI Creative Commons

Suming Wang,

Victor Zota,

Melanie Y. Vincent

et al.

npj Precision Oncology, Journal Year: 2024, Volume and Issue: 8(1)

Published: Dec. 3, 2024

Abstract Despite the development of cancer biomarkers and targeted therapies, most patients do not have a specific biomarker directly associated with effective treatment options. We developed VT1021 that induces expression thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to tumor microenvironment (TME). Our studies identified CD36 CD47 as dual can be used patient stratifying tools prognostic for treatment.

Language: Английский

Citations

0